Standard BioTools Regains Nasdaq Bid Price Compliance
LAB sits 32% above its 52-week low of $0.87.
Summary
Standard BioTools Inc. has announced it has regained compliance with Nasdaq's minimum bid price rule, resolving the previously reported delisting concern.
Key Events · Corporate Governance and Compliance · LAB
-
Regains Nasdaq Compliance
The company received a letter from Nasdaq confirming it has regained compliance with the minimum bid price requirement (Rule 5450(a)(1)).
-
Delisting Threat Removed
This resolves the previously reported non-compliance notice received on April 20, 2026, and removes the risk of delisting from the Nasdaq Global Select Market.
Analysis · LAB · Industrial Applications And Services
This 8-K announces that Standard BioTools has successfully regained compliance with Nasdaq's minimum bid price requirement, removing the previously disclosed delisting threat. This resolution is a positive development for investor confidence and ensures the company's continued listing on the Nasdaq Global Select Market.
At the time of this filing, LAB was trading at $1.15 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $448.9M. The 52-week trading range was $0.87 to $1.72. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.